Avon Pharmaceuticals Original NASH New Drug HPG1860 Approved by FDA Clinical Trials
Last Update: 2020-06-17
Search more information of high quality chemicals, good prices and reliable suppliers, visit
"FDA's approval of the first phase of the HPG1860 clinical trial is an important milestone for Avon PharmaceuticalsIn addition to NASH, the company's other original new drugs for HBV and HCC will continue to enter clinical research," said DrXu Xiaodong, CEO of the company, "HPG1860 Clinical Focus evaluates the safety of health volunteers after single and multiple oral dose sysage, pharmacokinetics and pharmacokinetic effects, HPG1860 has non-bile acid structure, high efficiency, high degree of selectivity, and fully excited FXAtron Pharmaceuticals is committed to the development of new drugs for liver diseases, especially non-alcoholic fatty hepatitis (NASH), chronically toxic hepatitis B and liver cancerNon-alcoholic fatty liver disease (NAFLD) is fast becoming the world's most common liver disease, with 20-25% of NAFLD patients further developing into NASHIn general, NASH is associated with liver fibrosis, which can develop over time into cirrhosis and liver cancerNASH is currently the second most common cause of liver transplantation in the United States and is expected to be the leading cause of liver transplantation by 2020.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to email@example.com
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.